The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Cleaner, for a moment, I thought you were giving up being a BioTech investor and going to stand for Parliament - (myself I would love to vote Labour but won't because of concerns about woke, immigration and defence).
But getting to the point, 'Robin' is well informed. Let's hope he's influential too.
BTW, a Starmer nightmare is not yet, a certainty IMO. ATB
Thanks very much indeed Burble.
I noticed from Cleaner's link that 'Kite' / Gilead are one of many affected by that FDA notice and recalled that 2017 acquisition, $11.9 billion https://www.gilead.com/news-and-press/press-room/press-releases/2017/8/gilead-sciences-to-acquire-kite-pharma-for-119-billion
A nice sum - reminds me of what values can be reached around here. I remember being astonished at the time.
(BTW Cleaner, I have edited over there to clarify).
Cleaner, to emphasise, no-one will be happy if ANY promising avenue against cancer falters, but, coupled with the (should stay 'unattributed') comments from a Moderna Exec, about Moderna being in trouble if Scancell are right. MMMmmmm One to ponder . . . GN
Good links Cleaner and thanks for the heads up. A new thread ! ATB
Burble ? But Ruck and Ray are not, either of them, a Dwarf - so I'm told.
Good try Ruck and nice to see your confusion after recent traumas, has gone.
Or has it ? ATB
I'm not sure about that C11 . . . . Oct 2021 https://www.lse.co.uk/rns/SCLP/notice-of-interim-results-uaayvfwz2joxnly.html
As we've had 'notice' the last 2 years, it's likely we'll get notice for Oct 2023 and on that subject, where the digger is it ? ATB
Balerno - advance notice of the Interims is usual so if there is notice this week the update will be next week or later. Re. the Investor briefing, as Violin suggests, I guess that has been overtaken by events, (for now).
Violin as always it's a wait for news ANY day . . . . . (and a tough wait for news everyday!).
So we have a 'pregnant silence' again, that being some 'calm before the storm', (which hopefully is about to transpire . . . . )
Very strange to see NO posts on a trading day.
A bit more data and the Interims report will be good to see.
(C7 good to see you punching as ever. ATB)
Nice one Cleaner and thanks to Burble too. If all goes well, Avidimab looks like a potential 'slam dunk' of the first order.
Perhaps with Patent lives in mind, 'time is of the essence'.
. . . or . . . https://uk.advfn.com/cmn/fbb/thread.php3?id=52251655
Yesterday 19/1 from the 'litter free' thread, over there, reply 33 onwards . . https://uk.advfn.com/cmn/fbb/thread.php3?
Supernumerary, Bermuda and Sci102 - (thanks to them). Bermuda concludes, "I'm assuming that even if they close the SCIB1 cohort to recruitment when they reach the required no. of responses, they'll still continue to dose, monitor and follow up all existing patients on that cohort in line with the trial protocol (dosing for 85 weeks and follow up for 2 years after first dose)so will still be gathering valuable data but in a few less patients and new patients can hopefully join the iSCIB1+ cohort."
I noted an earlier suggestion here, (by whom I don't remember), that recruitment to these trials could be completed before the end of Q2.
Chester, thanks for your replies to Defender about news to come. Nice reminders - yes there's some directions we know about and with 4 platforms bubbling, maybe some surprises too.
It's tantalising, watching and waiting every day, but one thing is for sure, a re-rating here is long overdue.
Thanks Burble - yes every word matters. You are right that the 'SCOPE' header could have been much more lively. Maybe a better header would not have made any material difference, BUT, you never know, and the point is, we need the same excellence in comms that we have in the Science.
'Every little helps' as they say.
It seems to me there's no real debate to be had about the timing of that brilliant news. So thank you MHRA and Scancell for letting us know asap.
The timing of the fund raise - well the sooner the better IMO and it takes some time to do I guess. So when it's 'in train' it happens and cash is now in the Bank and hooray for that!
WTP - Mia was right IMO but so were you. If the raise had been later, who knows what price it would have been at - the last RNS hasn't driven up the SP and no 'results' were imminent.
Burble - accepting your point but, honestly, a better heading would be nice but surely characters who don't read the RNS in full, are not serious players?
GNA
C7 I was delighted to see you posting again - that was a 4 month sabbatical.
You have 4,446 to reach 50,000 posts which would be quite a score. I hope to be 'minted' well before I get to 10,000 . . . .
Wishing you the best 2024.
JB not sure what you mean by that. I think EE's explanation of this RNS's timing in his 13.57 is probably the complete answer. But of course, Scancell might produce more news, anyday and now anytime apparently. And the 'Interims' to come shortly.
And thank you MHRA - what a pleasant contrast to the mysterious and neverending wait for ICHOR approval in the USA, some long time ago!
EE thanks for the heads up and posts today.
Morning Cleaner - someone here a while ago, wrote a really excellent summary dealing with the expense, difficulties and impracticality of the 'personalised vaccines' approach, in comparison to the simplicity of the Scancell 'way'.
I can't recall who it was, Burble, Johnny, Bermuda maybe? I've tried to find it but I can't. Do you remember who it was?
It would be good to see it again.
The UK Govt's devotion and support to the USA's Moderna giant is painful to see, knowing what we here 'know' . . . . (or think we know . . . )
Yes Cleaner - Moderna are firmly in the driving seat with the UK Govt., but a reported comment, 'if you (Scancell) are right, we (Moderna) are in trouble' comes to mind.
Trouble is our middle name !
Hi Chester - hopefully, "Our new found investors will have the appetite for a little more", or, they 'may' have . . . .
Same as you I'm delighted to see more Investors on board and there's the possibility that development is connected to Sath, our CFO, attending JPM. What comes of that, we may see.
I too am hoping for positive results from the next data.